AXIM Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 geg. 2024 @ 22:53):

Stats
Dzisiejszy wolumen	214 813
Średni wolumen	576 236
Kapitalizacja rynkowa	3.06M
EPS	$0.000690 ( 2023-11-20 )
Następna data zysków	( $0 ) 2024-05-22
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.270
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Huemoeller John Walter Ii	Buy	250 000	Convertible Note
2024-03-15	Valencia Catalina	Buy	7 837 500	Convertible Note
2024-03-15	Schroeder Blake	Buy	35 000	Convertible Note
2024-03-15	Cunningham Robert L	Buy	35 000	Convertible Note
2024-03-15	Scott Timothy Richard	Buy	35 000	Convertible Note

INSIDER POWER
100.00
Last 56 transactions
Buy: 36 148 017 \| Sell: 23 000 000

AXIM Biotechnologies, Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

AXIM Biotechnologies, Finanse

Annual	2023
Przychody:	$39 518.00
Zysk brutto:	$-387 501 (-980.57 %)
EPS:	$-0.0354

FY	2023
Przychody:	$39 518.00
Zysk brutto:	$-387 501 (-980.57 %)
EPS:	$-0.0354

FY	2022
Przychody:	$8 875.00
Zysk brutto:	$-417 251 (-4 701.42 %)
EPS:	$-0.0360

FY	2021
Przychody:	$60 460.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.120

Financial Reports:

No articles found.

AXIM Biotechnologies,

AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and oncology. The company is developing rapid diagnostic tests, which measure the levels of functional neutralizing antibodies that prevent SARS-CoV-2 from attaching to human cells; serological diagnostic test, which detect neutralizing antibodies that measure adaptive immune response to the SARS-CoV-2 virus; and tests for management of COVID-19 Patients to detect biomarkers related to inflammation. It is also developing rapid quantitative tear tests for Matrix metalloproteinase-9, an inflammatory biomarker for dry eye disease; SBI-183, an anti-metastatic compound suppressing tumor cell growth and blocking metastasis; and SPX-1009, an anti-metastatic treatment to measure levels of quiescin sulfhydryl oxidase I. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.